Abstract 28P
Background
Trophoblast cell surface antigen 2 (TROP2) is a cell surface glycoprotein expressed in many types of cancers, and its overexpression is associated with poor prognosis. Antibody-drug conjugates that target TROP2 represent a promising approach for the treatment of TROP2-expressing cancers. However, clinical significance of TROP2 expression in lung adenocarcinoma (LUAD) has not been fully elucidated.
Methods
Immunohistochemical (IHC) staining with an anti-TROP2 antibody (SP295) was performed in 1196 surgically resected LUAD tissue microarrays. The intensity of TROP2 expression was scored as 0 (absent), 1 (weak-to-moderate), and 2 (strong). The H-score was defined as the product of the intensity and proportion of positive tumor cells. The positivity of TROP2 expression was evaluated based on the intensity (0 vs. 1/2), proportion of positive tumor cells (<25% vs. ≥25%), and H-score (<50 vs. ≥50). The association of TROP2 overexpression with clinicopathological and molecular characteristics and prognosis was statistically analyzed.
Results
TROP2 overexpression was observed in 916 patients (77%) showing intensity 1/2, 424 (35%) showing positive tumor cells ≥25%, and 268 (22%) showing H-score ≥50. The overall survival of patients with TROP2-positive LUADs was significantly worse than those with TROP2-negative LUADs as the proportion of positive tumor cells or H-score was used as a positive criterion. TROP2 overexpression was significantly associated with men, smoker, advanced pathological stage (stage ≥II), larger tumor size (≥3 cm), lymphatic permeation, vascular invasion, pleural invasion, EGFR wild-type, KRAS mutation, and PD-L1-positive expression.
Conclusions
TROP2 overexpressed LUADs are biologically aggressive tumors and good candidates for TROP2-targetting therapy. The proportion of positive tumor cells and H-score may be useful for patient selection.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
36P - Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition
Presenter: Anmi Jose
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
Presenter: Alfonso Esposito
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - MicroRNA as a promising molecular biomarker for liquid biopsy in breast cancer
Presenter: Giorgia Vesca
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Patient-based models to study infiltration heterogeneity in gliomas
Presenter: Ivana Manini
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - HER2 aberration as a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer
Presenter: Thomas Samer Tarawneh
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - Promising epi(genetic) biomarkers for ovarian tumor prognosis
Presenter: Ieva Vaicekauskaitė
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy
Presenter: Monika Skupinska
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Early cancer detection from liquid biopsy using cell-free RNA
Presenter: Joao Curado
Session: Cocktail & Poster Display session
Resources:
Abstract